Personalized radiation: scans could guide higher doses to aggressive tumors

NCT ID NCT04846309

Recruiting now Knowledge-focused Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether a special PET scan (FMISO-PET) can identify oxygen-deprived (hypoxic) areas in esophageal tumors, which are harder to treat. Patients with hypoxic tumors receive a higher radiation dose, while others get standard care. The study aims to see if this personalized approach is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FMISO-PET scan and MRI
What this could lead to: If successful, this approach could allow doctors to tailor radiation doses to each patient's tumor, potentially improving outcomes.
What could go wrong: This is a very early Phase 1 trial with only 16 participants, focused on safety. It may not lead to better survival or become standard practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Locations

Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.